Tempus unveils AI-enabled personal health concierge app

Tempus, an AI-powered data company involved in advancing precision medicine, has launched olivia, an AI-enabled personal health concierge app aimed at empowering patients by centralizing patients’ health data and making that data accessible and actionable through AI.
The app will allow patients to bring their health information into one combined platform.
Additionally, patients will be able to connect directly to over 1,000 health systems via EHR integration, sync data from health devices to track daily metrics and manually upload health records. In a statement, the company explained that olivia organizes data into a dynamic timeline where patients can access their records, including lab results, imaging reports, visit summaries and deep clinical data.
They can also obtain digital imaging and communications in medicine (DICOM) images, which can be shared directly with a patient’s care team.
Moreover, according to the company, olivia’s AI-enabled capabilities will permit patients to ask questions regarding their records, summarize their health information and receive responses informed by their data.
For example, patients can query, “summarize my health status,” and olivia will give them a concise summary of information in their health data.
Olivia also connects to external resources, including clinicaltrials.gov, to supplement the personalized insights offered from existing health data.
“At Tempus, our goal has always been to improve patient outcomes by harnessing the power of data and AI,” Eric Lefkofsky, founder and CEO of Tempus, said in a statement.
“Now, as AI becomes increasingly integrated into healthcare, tools like olivia will be essential in helping patients understand and navigate their care. This app goes beyond organizing information; it’s a proactive partner empowering patients to steer their health with confidence and clarity.”
THE LARGER TREND
In 2023, Tempus and Pfizer announced a multiyear strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology.
Pfizer will leverage Tempus’ library of de-identified data to accelerate therapeutic development in oncology. It will also use Tempus’ AI-driven companion diagnostic offerings and clinical trial-matching program to support therapeutic research and development.
In 2022, GSK announced a three-year agreement with a $70 million initial payment to expand its access to Tempus’ AI-powered data library.
The deal included its de-identified patient data. GSK said the collaboration allows it to leverage the U.S.-based company’s library to accelerate drug discovery in oncology, improve its clinical trial design, identify drug targets and speed up trial enrollment.
link